News
Orbital Sciences Corp (ORB) Grows Satellite and Space-Cargo Business Organically
May 24, 2013Orbital Sciences Corp (ORB) manufactures satellites and launches rockets in the defense industry and provides NASA with much-needed services, and the company displays encouraging financial metrics at a time when interest in space travel is on the rise, says Michael F. Ciarmoli, Vice President and Equity Research Analyst at KeyBanc Capital Markets Inc. “The one top pick we have on the defense side is ‘buy’-rated Orbital Sciences, a name that’s performed very well year to date. They are a rocket-launch provider and a satellite manufacturer, one of the better organic stories in the defense sector, and also a key provider to NASA for its cargo-delivery services...
more
Precision Castparts Corp. (PCP) Largely Exposed to Boeing 787 Manufacturing
May 24, 2013Precision Castparts Corp. (PCP) has large exposure to the continuing manufacturing of Boeing 787 aircraft, with the fundamentals and demand remaining largely intact despite global macroeconomic concerns, says Michael F. Ciarmoli, Vice President and Equity Research Analyst at KeyBanc Capital Markets Inc. “We also recently upgraded Precision Castparts to ‘buy,’ probably one of the higher-quality management teams, one of the more unique and differentiated business models in the sector. It’s a larger-cap name, $27 billion market cap, but when we’re looking at this mix of which companies are leveraged to the OE production cycle, we really do favor Precision Castparts‘ end-market profile: A lot of exposure to the Boeing 787, roughly $12 million of content, so as that platform begins to ramp up to 10 per month in the latter portion of 2013 and into 2014, we see PCP being a big beneficiary,” Ciarmoli said...
more
QUALCOMM, Inc. (QCOM) Benefits from Positive ASP Trend, Collects Royalties on 3G, 4G Smartphones
May 24, 2013QUALCOMM, Inc. (QCOM) is seeing opportunities in the smartphone space as it collects royalties on all 3G and 4G smartphones, based on application service providers that are still a positive trend in the segment, says Ian Ing, Vice President and Senior Analyst at Lazard Capital Markets. “[QUALCOMM sells] both chipsets as well as collect royalties on all 3G, 4G smartphones that are being sold. I think the opportunity is still being underestimated. The royalties they collect are based on device ASPs for these handsets, and I think there is still a lot of support for very high device ASPs in these flagship smartphones,” Ing said. FOR MORE INFORMATION ABOUT THIS INTERVIEW CLICK HERE...
more
Xilinx, Inc. (XLNX) Expands End Market for FPGAs, Enters $10 Billion TAM with Embedded Processors
May 24, 2013Xilinx, Inc. (XLNX) is expanding the end markets they sell their FPGAs into by developing midtier parts for comm infrastructure and integrating embedded processors into their circuits, says Ian Ing, Vice President and Senior Analyst at Lazard Capital Markets. “Xilinx sells parts called FPGAs, and these are broadly exposed into a lot of different end markets…number one, they’ve developed sort of midtier parts that go into a lot of comm infrastructure. Midtier parts do really well in things like wireless base station radio cards, because they have lower cost, low power and good-enough performance, and that’s attractive for the applications right now,” Ing said...
more
Acute Myeloid Leukemia (AML) Treatment in Phase III Trials: Cyclacel (CYCC) CEO and CFO Buy Stock
May 23, 2013There have been several highly successful biotech companies formed from the patent libraries of universities and from research institutes. Often these are private companies owned by the clinical researchers and the institutions that fund them, but occasionally these companies are registered in the public markets and are available for general investment. Cyclacel Pharmaceuticals (CYCC) was formed in 1997 to exploit several biotech innovations developed at the University of Dundee. In an interview from September of last year in The Wall Street Transcript, Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, stated that, “Our lead drug, sapacitabine, is now in a pivotal Phase III trial for acute myeloid leukemia, or AML, a disease of mostly elderly people… sapacitabine offers to patients with AML … the first drug in its class to be given by mouth...
more
Page 1 | Next 5 | Page 202
